dc.contributor.author | Donners, R | |
dc.contributor.author | Figueiredo, I | |
dc.contributor.author | Westaby, D | |
dc.contributor.author | Koh, D-M | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Carreira, S | |
dc.contributor.author | de Bono, JS | |
dc.contributor.author | Fotiadis, N | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-03-13T10:41:11Z | |
dc.date.available | 2024-03-13T10:41:11Z | |
dc.date.issued | 2023-12-15 | |
dc.identifier | ARTN 121 | |
dc.identifier | 10.1186/s40644-023-00644-w | |
dc.identifier.citation | Cancer Imaging, 2023, 23 (1), pp. 121 - | |
dc.identifier.issn | 1740-5025 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6188 | |
dc.identifier.eissn | 1470-7330 | |
dc.identifier.eissn | 1470-7330 | |
dc.identifier.doi | 10.1186/s40644-023-00644-w | |
dc.identifier.doi | 10.1186/s40644-023-00644-w | |
dc.description.abstract | BACKGROUND: Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate target lesion selection in mCRPC patients with sclerotic bone disease for subsequent CT-guided bone biopsies. METHODS: 20 CT-guided bone biopsies were prospectively performed between 02/2021 and 11/2021 in 17 mCRPC patients with only sclerotic bone disease. Biopsy targets were selected based on MRI, including diffusion-weighted (DWI) and T1-weighted VIBE Dixon MR images, allowing for calculation of the apparent diffusion coefficient (ADC) and the relative fat-fraction (rFF), respectively. Bone marrow with high DWI signal, ADC < 1100 µm2/s and rFF < 20% was the preferred biopsy target. Tumor content and NGS-feasibility was assessed by a pathologist. Prognostic routine laboratory blood parameters, target lesion size, biopsy tract length, visual CT density, means of HU, ADC and rFF were compared between successful and unsuccessful biopsies (p < 0.05 = significant). RESULTS: Overall, 17/20 (85%) biopsies were tumor-positive and next-generation genomic sequencing (NGS) was feasible in 13/18 (72%) evaluated samples. Neither laboratory parameters, diameter, tract length nor visual CT density grading showed significant differences between a positive versus negative or NGS feasible versus non-feasible biopsy results (each p > 0.137). Lesion mean HU was 387 ± 187 HU in NGS feasible and 493 ± 218 HU in non-feasible biopsies (p = 0.521). For targets fulfilling all MRI selection algorithm criteria, 13/14 (93%) biopsies were tumor-positive and 10/12 (83%) provided NGS adequate tissue. CONCLUSIONS: Multiparametric bone MRI can facilitate target lesion selection for subsequent CT-guided bone biopsy in mCPRC patients with sclerotic metastases. TRIAL REGISTRATION: Committee for Clinical Research of the Royal Marsden Hospital registration number SE1220. | |
dc.format | Electronic | |
dc.format.extent | 121 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BMC | |
dc.relation.ispartof | Cancer Imaging | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Bone marrow | |
dc.subject | Computer tomography | |
dc.subject | Genomics | |
dc.subject | Image-guided biopsy | |
dc.subject | Neoplasms | |
dc.subject | Male | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Image-Guided Biopsy | |
dc.subject | Tomography, X-Ray Computed | |
dc.subject | Magnetic Resonance Imaging | |
dc.subject | Bone Diseases | |
dc.title | Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-12-04 | |
dc.date.updated | 2024-03-13T10:40:44Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1186/s40644-023-00644-w | |
rioxxterms.licenseref.startdate | 2023-12-15 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38102655 | |
pubs.issue | 1 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1186/s40644-023-00644-w | |
pubs.volume | 23 | |
icr.researchteam | Cancer Biomarkers | |
icr.researchteam | PrCa Targeted Therapy | |
dc.contributor.icrauthor | Westaby, Daniel | |
dc.contributor.icrauthor | Carreira, Suzanne | |
dc.contributor.icrauthor | De Bono, Johann | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Dr Nicolo Battisti) on 2024-03-13. Deposit type is initial. No. of files: 1. Files: Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resis.pdf | |